Clinical expression of primary Sjögren's syndrome in adult patients diagnosed at an age less than or equal to 35 years versus those older than 35 years
Abstract
Objective: to describe and compare the clinical manifestations, in adult patients diagnosed with primary Sjögren’s Syndrome at age less than or equal to 35 years versus those over 35 years of age. Materials and Methods: we analyzed the data of patients older than 18 years, with diagnosis of primary Sjögren’s syndrome (American-European criteria 2002), included in the GESSAR database (Sjögren Syndrome Study Group of the Argentine Society of Rheumatology). Results: 665 patients were included. One hundred of them with an age at diagnosis less than or equal to 35 years and with a mean age at diagnosis of 29 + 4 years, 92% of them women. The average age at diagnosis of the group over 35 years was 54 + 11 years, 96% women. Statistically significant differences were found between less than or equal to 35 years vs over 35 years, in xerophthalmia (90.72% vs 95.64%, p: 0.04) and xeroderma (42.35% vs 57.36% , p: 0.03), and in the following domains of ESSDAI (EULAR Activity Index for primary Sjögren’s syndrome): peripheral nervous system (4.05 vs 11.32, p: 0.03), respiratory (6% vs 15.40%, p : 0.01) and renal (6% vs. 1.59%, p: 0.02). Conclusion: our study suggests less glandular involvement in patients with pSS diagnosed at a younger age, without a characteristic differential pattern regarding systemic involvement.References
I. Brito-Zerón Pilar y Ramos-Casals Manuel. Evolución y pronóstico del paciente con Síndrome de Sjögren Primario. Med Clin (Barc). 2008; 130 (3):109-15.
II. Haga HJ1, Jonsson R. The influence of age on disease manifestations and serological characteristics in primary Sjögren’s syndrome. Scand J Rheumatol. 1999; 28(4):227-32.
III. Ramos-Casals, M., Cervera, R., Font, J., Garcóa-Carrasco, M., Espinosa, G., Reino, S., Ingelmo, M. (1998). Young Onset of Primary Sjögren’s syndrome: clinical and immunological characteristics. Lupus 1998, 7(3), 202–206.
IV. Seror R, Theander E, Brun JG, et al. Validation of EULAR primary Sjögren’s syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015; 74:859–66.
V. Ramos-Casals Manuel, Brito-Zero Pilar, Solans R., Camps María-Teresa. Systemic involvement in primary Sjögren’s syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). Rheumatology 2014; 53:321-331.
VI. M Ramos-Casals, A G Tzioufas, J Font. Primary Sjögren’s syndrome: new clinical and therapeutic concepts. Ann Rheum Dis 2005; 64:347–354. doi: 10.1136/ard.2004.025676.
VII. Ramos-Casals Manuel, Solans R., MD, Ph, Rosas J. Primary Sjogren Syndrome. Immunologic Expression in 1010 Patients. Medicine. 2008; 87 (4).
VIII. Chisholm D. M., Mason D. K.. Labial salivary gland biopsy in Sjögren’s disease. J Clin Pathol. 1968 Sep; 21(5): 656–660. doi:10.1136/jcp.21.5.656.
IX. Seror R, Bowman SJ, Brito-Zeron P, et al. EULAR Sjögren’s syndrome disease activity index (ESSDAI): a user guide. RMD Open 2015;1:e000022.doi:10.1136/rmdopen-2014-000022.
X. Sormani de Fonseca L., Romanini F.E.,Auad C. Síndrome de Sjögren. Reumatología/ Maldonado Cocco y Gustavo Citera. 1º edición. Martinez. Ediciones Azzurras. 2010. Capítulo 25: 252- 277.
XI. An Y, Zhang XW, Li ZG. Clinical features of primary Sjogren syndrome in youth. Beijing Da Xue Xue Bao Yi Xue Ban. 2009 Jun 18; 41(3):324-7.
XII. Anquetil C., Hachulla E., Machuron F. Is early-onset primary Sjögren’s syndrome a worse prognosis form of the disease? Rheumatology doi/10.1093/rheumatology/key392/5250863 by INSEAD 18 December 2018.
XIII. Secco A, Pellet AC. Consenso argentino de diagnóstico y tratamiento de síndrome de Sjögren primario. Rev. Arg. Reumatol. pp, 1–108 (2017).
Copyright (c) 2021 Intellectual property rights: authors. Reproduction rights: Argentine Society of Rheumatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
